MPI — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL92179	0.34	7/20
SCHEMBL50008	0.55	5/20
SCHEMBL212369	0.49	5/20
SCHEMBL213134	0.49	5/20
SCHEMBL212961	0.47	5/20
SCHEMBL213177	0.47	5/20
SCHEMBL213424	0.47	5/20
SCHEMBL213624	0.47	5/20
SCHEMBL215250	0.47	5/20
SCHEMBL212968	0.47	5/20
SCHEMBL212829	0.44	4/20
SCHEMBL213778	0.42	4/20
SCHEMBL212157	0.41	4/20
SCHEMBL212158	0.41	4/20
SCHEMBL113821	1.00	3/20
SCHEMBL113820	0.65	3/20
SCHEMBL254012	0.47	3/20
Apomorphine (SCHEMBL8524)	1.00	2/20
Apomorphine (SCHEMBL232473)	1.00	2/20
Apomorphine (SCHEMBL8525)	0.93	2/20

Clinical trials — most relevant to MPI by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.	PHASE4	UNKNOWN
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD	PHASE4	RECRUITING
Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age	PHASE4	COMPLETED
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma	PHASE3	COMPLETED
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis	PHASE3	COMPLETED
A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)	PHASE3	COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old	PHASE2	COMPLETED
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA	PHASE1/PHASE2	COMPLETED
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia	PHASE1	WITHDRAWN
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia	PHASE1	WITHDRAWN
18F-FMPP PET MPI in the Detection of Coronary Artery Disease	EARLY_PHASE1	UNKNOWN
Plasma Mannose Associated Parameter Levels in Nondiabetic Coronary Artery Disease	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Circadian Brown Adipose Tissue Metabolism	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma	nan	COMPLETED
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer	nan	UNKNOWN
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology	nan	COMPLETED
Pediatric Arthropathy Beyond Inflammation: Clinical Spectrum and Diagnostic Approach at Assiut University Children Hospital	nan	NOT_YET_RECRUITING
Natural History Study Protocol in PMM2-CDG (CDG-Ia)	nan	ACTIVE_NOT_RECRUITING
Characterization of the Patient Population With Galactosialidosis	nan	COMPLETED
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease	nan	UNKNOWN
Screening of Lysosomal Storage Disorders Diseases in Minority Groups	nan	UNKNOWN
The Effects of Acetyl-L-Carnitine and Myo/Chiro-Inositol in Patients With PCOS	nan	COMPLETED
A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)	nan	COMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte	nan	COMPLETED
Evaluating DyNamic Myocardial Blood Flow QUantitation As a Cost Effective Care ModeL for DiabEtic Patients With Coronary Artery DiSease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MPI binder may also engage these)

Protein	Name	Similarity
Q3SZI0	—	1.000	Q3SZI0 →
A5A6K3	—	1.000	A5A6K3 →
Q924M7	—	1.000	Q924M7 →
Q68FX1	—	1.000	Q68FX1 →
Q8HXX2	—	0.998	Q8HXX2 →
Q66WM4	—	0.972	Q66WM4 →
O43014	—	0.971	O43014 →
Q870Y1	—	0.970	Q870Y1 →
Q5EAD2	—	0.968	Q5EAD2 →
A2VD33	—	0.966	A2VD33 →
P29952	—	0.966	P29952 →
P29951	—	0.966	P29951 →
Q75AB5	—	0.965	Q75AB5 →
A5GFY8	—	0.964	A5GFY8 →
Q6PI48	—	0.964	Q6PI48 →
Q9GZT8	—	0.964	Q9GZT8 →
Q6NUA1	—	0.963	Q6NUA1 →
Q8QZS1	—	0.963	Q8QZS1 →
P34650	—	0.963	P34650 →
Q61753	—	0.962	Q61753 →
P31254	—	0.962	P31254 →
F4ZGF2	—	0.962	F4ZGF2 →
Q8CIG8	—	0.962	Q8CIG8 →
PRMT5	Protein arginine N-methyltransferase 5	0.962	landscape →
Q58H57	—	0.962	Q58H57 →
Q5XIE6	—	0.962	Q5XIE6 →
D4AAT7	—	0.962	D4AAT7 →
Q9LZM3	—	0.961	Q9LZM3 →
O08651	—	0.961	O08651 →
Q5R698	—	0.961	Q5R698 →